LingVo.club
📖+10 XP
🎧+10 XP
+15 XP
New mucosal EV vaccine with inverted HA may protect against many flu strains (Level A1) — Microscopic image depicts a virus.

New mucosal EV vaccine with inverted HA may protect against many flu strainsCEFR A1

8 Apr 2026

Adapted from LaTina Emerson-Georgia State, Futurity CC BY 4.0

Photo by Am, Unsplash

Level A1 – Beginner
2 min
69 words
  • Scientists report a new vaccine for the flu.
  • The vaccine may protect against many flu viruses.
  • It uses tiny particles made by cells.
  • These particles carry a changed flu protein.
  • The vaccine is given through the nose.
  • It protects the breathing passages and body.
  • The vaccine makes antibodies and immune cells.
  • Tests in mice showed good protection.
  • This idea could help in epidemics and pandemics.
  • More research is needed.

Difficult words

  • vaccinemedicine that helps the body fight infection
  • protectkeep someone or something safe from harm
    protects
  • particlea very small piece of matter
    particles
  • proteina natural substance in cells and bodies
  • antibodya protein the body makes to fight germs
    antibodies
  • pandemica disease that spreads to many countries
    pandemics

Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.

Discussion questions

  • Would you take a vaccine through your nose?
  • Have you ever had a flu vaccine?
  • Do you think more research is needed?

Related articles

Nanotech biosensors for early disease diagnosis (Level A1)
9 Jul 2026

Nanotech biosensors for early disease diagnosis

At the 75th Lindau Meeting, South African scientist Jaymi Leigh January presented nanotechnology-based biosensors that detect tiny disease biomarkers for tuberculosis, cancer and viral conditions. She aims to develop affordable, portable diagnostics suited to local health needs in South Africa.

AI finds new target for monkeypox (Level A1)
28 Dec 2025

AI finds new target for monkeypox

Researchers used artificial intelligence to identify a viral protein called OPG153 that many antibodies bind. Laboratory tests and mouse studies confirmed the finding, which could help develop cheaper vaccines or antibody treatments.